The HACEK group of bacteria -Haemophilus parainfluenzae, Aggregatibacter spp. (A. actinomycetemcomitans, A. aphrophilus, A. paraphrophilus, and A. segnis), Cardiobacterium spp. (C. hominis, C. valvarum), Eikenella corrodens, and Kingella spp. (K. kingae, K. denitrificans)are fastidious gram-negative bacteria, part of the normal microbiota of oral and upper respiratory tract in humans. Although their pathogenicity is limited, they are responsible for 1-3% of all infective endocarditis. HACEK endocarditis mostly affect patients with underlying heart disease or prosthetic valves, and are characterized by an insidious course, with a mean diagnosis delay of 1 month (Haemophilus spp.) to 3 months (Aggregatibacter and Cardiobacterium spp.). The advent of continuously monitored blood culture systems with enriched media has erased the need for extended incubation for the diagnosis of HACEK endocarditis. Medical treatment relies on third generation cephalosporin, with a favourable outcome in 80-90% of cases, with or without cardiac surgery.
Several recent microbiological evolutions are remarkable: i) the development of enriched blood cultures (BC) media and the implementation of automated BC systems, that has erased the need for extended incubation for the diagnosis of HACEK IE [10 11] ; ii) easier and reliable identification from cultures thanks to the MALDI-TOF mass spectrometry technology regardless of the system used (Microflex LT [Bruker Daltonics] or Vitek MS [bioMérieux]), with species-and genus-level identification in 66-93% and 88-95% cases, respectively [12] [13] [14] [15] ; iii) rapid molecular-based detection directly from clinical specimens using home-made protocols or commercially-available kits [16 17] ; and iv) recent clinical and laboratory standards institute (CLSI) recommendations for antimicrobial susceptibility testing of the HACEK group using the broth microdilution technique [CLSI M45-A2 2010].
Haemophilus parainfluenzae
H. parainfluenzae is the most common cause of HACEK endocarditis, found in 28 (36%) of the 77 cases of HACEK endocarditis enrolled within the International Collaboration on Endocarditis (ICE) prospective cohort study during years 2000-2006 [7] , and 12 out of 45 (27%) cases of HACEK IE reported from the Mayo Clinic in Rochester, during years 1970-1992 [2] . The association between H. parainfluenzae bacteremia and IE is strong, with a positive predictive value (PPV) for the diagnosis of IE estimated at 55% (10/18) [4] .
Microbiology
H. parainfluenzae is a small, non-motile, non-spore-forming, non-acid-fast, pleomorphic gramnegative bacilli, which requires for growth V factor or nicotinamide (complexed as NAD or NADP), present in erythrocytes. Members of the Pasteurellaceae family, Haemophilus spp. are part of the normal upper and lower respiratory tract microbiota, H. parainfluenzae accounting for 75% of Haemophilus species in both oral cavity and pharynx. H. parainfluenzae has very rarely been associated with human infections and most case reports of non-IE infections were related to its primary reservoir, respiratory tract (e.g. sinusitis, bronchitis, otitis, exacerbation of chronic obstructive pulmonary disease, pneumonia), although H. parainfluenzae brain abscess, surgical site infections, soft tissue infections, prosthetic joint infections, and hepatic and biliary tract infections have also been documented [18] . H. parainfluenzae may also be part of the genital tract microbiota, and documented cases of chorio-amniotitis, and neonatal sepsis have been reported.
A Canadian study of 37 clinical isolates of H. parainfluenzae originating from blood cultures, or abscess fluid, found susceptibility rates of 67.6% for penicillin, 97.3% for ampicillin, and 100% for amoxicillin-clavulanic acid, ceftriaxone, meropenem, and levofloxacin [19] .
Characteristics of H. parainfluenzae endocarditis
A series of 26 cases of H. parainfluenzae endocarditis was reported in 1997, associated with a literature review of 26 additional cases [20] . Most patients (60% in the series) had underlying native valve disease, the remaining predisposing factors being prosthetic valve (12%), or previous infective endocarditis (10%). Of note, only one patient (2% of all cases of Haemophilus spp. endocarditis reported in this series) was an intravenous drug user (IVDU), while 38% of previously reported cases (15/40) occurred in IVDU. Portal of entry remained unknown in 75% of all cases.
The mean duration from symptoms onset to diagnosis was quite long, at 34 days (range 2-330) in the series, and 37 days (range 5-365), for the cases previously reported. This diagnosis delay, possibly related to the insidious onset of symptoms and the subacute clinical course, may be one of the reason behind the high proportion of patients who present with symptomatic peripheral embolization (~50%), and large vegetation(s), > 10 mm in 42% of cases [20 21 ]. On the other hand, the proportion of patients with perivalvular abscess (7%), and heart failure (15-30%) is rather low as compared to usual figures in infective endocarditis, which may be related to the limited pathogenicity of these organisms. The mitral valve is most commonly affected in non-IVDU patients (71%), while the tricuspid valve is primarily involved in IVDU (45%). Data from two different cohorts suggested that H. parainfluenzae endocarditis was less likely to have an insidious onset than A. actinomycetemcomitans and C. hominis [2 7 ].
Despite the diagnosis delay, and the high proportion of patients with large vegetation(s), and/or peripheral embolization, the overall prognosis of patients with H. parainfluenzae endocarditis is favourable in most cases: attributable mortality was estimated at 5% in the largest series reported to date [20] , and 10% in the literature review. Surgical valvular replacement was performed in 40-70% of cases. Most patients have been treated with a β-lactam agent (mostly third-generation cephalosporin during recent years [7] , in agreement with international guidelines [22] ). However, the outcome of medically treated patients was also favourable in most cases in older series, when amoxicillin and ampicillin, usually combined with an aminoglycoside, were more commonly used [2 20 ].
Aggregatibacter spp.
The three species A. actinomycetemcomitans, A. aphrophilus, and A. segnis are the second most common cause of HACEK endocarditis, found in 26 (34%) of the 77 cases of HACEK endocarditis enrolled within the ICE prospective cohort study [7] , and 16 out of 45 (36%) cases of HACEK endocarditis reported from the Mayo Clinic [2] . The association between Aggregatibacter spp. bacteremia and endocarditis is strong, with a PPV for the diagnosis of IE estimated at 100% (22/22) for A. paraphrophilus and A. actinomycetemcomitans, and 55% (5/9) for A. aphrophilus, in a landmark New Zealand study [4] .
Microbiology
Aggregatibacter spp. also belong to the Pasteurellaceae family and are facultatively anaerobic, non-motile, coccoid to rod-shaped, gram-negative bacteria. They are part of the normal microbiota of the human oral cavity, especially dental plaque. The genus Aggregatibacter was created in 2006, bringing together several former species of the Actinobacillus (A. actinomycetemcomitans) and
Haemophilus (H. aphrophilus, H. paraphrophilus, and H. segnis) genera [23] . Note that the former species H. paraphrophilus corresponds now to V factor-dependent H. aphrophilus strains and is now classified within the species A. aphrophilus [23] . A. actinomycetemcomitans is particularly common in the gingival and supragingival crevices, and is a frequent cause of aggressive periodontitis [24] . In addition, as inferred from its name, A. actinomycetemcomitans is commonly isolated concomitantly with members of the Actinomycetes group in abscess and wound specimens from actinomycotic lesions [25] . A. paraphrophilus is a normal inhabitant of the nasopharynx, oropharynx, mouth, lower gastro-intestinal tract, and vagina of mature women. Besides IE, A. paraphrophilus has mainly been documented from abscess (especially brain abscess), but also bone or joint infections, and endophtalmitis [18] . Likely underestimated due to misidentifications by conventional methods, A. segnis may also cause endocarditis as well as bacteremia and pyelonephritis [26 27 ].
A study of 11 clinical isolates of A. aphrophilus found susceptibility rates of 82% for penicillin, and 100% for ampicillin, amoxicillin-clavulanic acid, ceftriaxone, meropenem, and levofloxacin [19] .
Of note, the only HACEK organism resistant to penicillin in the ICE-prospective cohort study was one isolate of A. aphrophilus [7] .
Characteristics of Aggregatibacter spp. endocarditis
The first case of A. actinomycetemcomitans endocarditis was published in 1964, and a literature review of 102 cases of A. actinomycetemcomitans endocarditis published 40 years later found that: i) A. actinomycetemcomitans endocarditis mostly occurred in men (two thirds of all reported cases), with a mean age of 47 years; ii) risk factors mostly included underlying valve disease (75% of all cases, secondary to rheumatic heart disease in half of patients), and prosthetic valve (26%); iii) a dental disease was frequently associated (42%); iv) the disease was particularly insidious, with a mean diagnosis delay of 13 weeks after symptoms onset; v) the aortic valve was more commonly affected (51%), than the mitral valve (33%); vi) complications were not rare (63%), and mostly included emboli (30%), and heart failure (27%); vii) surgical valvular replacement was required in 25% of cases, and viii) the overall mortality rate was 18% [28] . When compared to other HACEK endocarditis within the ICE-prospective cohort study, A. actinomycetemcomitans endocarditis was more likely to occur on prosthetic valves (10/15, 67%), with a diagnosis delay > one month (8/15, 53%) , and to be associated with Osler's nodes [7] .
Other Aggregatibacter species are less common causes of endocarditis, and available data remain scarce: A review of 23 cases of A. aphrophilus endocarditis published in 1975 -then referred to as Haemophilus aphrophilus -was remarkable for the high mortality rate (48%) [29] . A review of 17 cases of A. paraphrophilus endocarditis published in 1995 -then referred to as Haemophilus paraphrophilus -was remarkable for the predominance of mitral valve endocarditis (16/17), while the mortality rate was in the usual range for IE, at 18% [30] .
Cardiobacterium spp.
Cardiobacterium spp. are the third most common agents responsible for HACEK endocarditis, found in 11 (14%) of the 77 cases of HACEK endocarditis enrolled within the ICE prospective cohort study [7] , and 12 out of 45 (27%) cases of HACEK endocarditis reported from the Mayo Clinic [2] . Although C. hominis is by far the most common Cardiobacterium species involved, a few cases of C. valvarum endocarditis have been reported since it was first identified in a patient with bicuspid aortitis and ruptured mycotic cerebral aneurysm, in 2004 [31] . The association between C. hominis bacteremia and endocarditis is strong, with a PPV for the diagnosis of endocarditis estimated at 88% (7/8) in one study [4] , and 94% (32/34), or 95% (60/63) in two large literature reviews [32 33 ].
Microbiology
Cardiobacterium spp. belong to the Cardiobacteriaceae family and consist of facultatively anaerobic, non-motile, gram-negative rods. After gram staining, they appear as pairs, short chains, teardrop forms, rosettes, or clusters -sometimes with bulbous ends. The normal habitat of these species is the human oral cavity and nasopharynx. Cardiobacterium spp. have also been isolated from the genital tract of asymptomatic women. These organisms are of low virulence, and their pathogenic effect is mostly limited to IE in humans. Inocula as great as 10 9 microorganisms injected into various mice, rabbits, hamsters, guinea pigs, and pigeons, failed to produce any evidence of infection [33] . Note that one case of prosthetic valve endocarditis was reported following upper gastrointestinal endoscopy [34] .
Although most clinical isolates of Cardiobacterium spp. investigated to date were susceptible to penicillin and ampicillin, rare reports of β-lactamase-producing C. hominis strains causing endocarditis [35 36] , have led to the recommendation that third-generation cephalosporins must be considered as the first-line antibacterial treatment of Cardiobacterium spp. endocarditis.
Characteristics of Cardiobacterium spp. endocarditis
In 2005 and 2006, two large reviews of 63 and 67 cases of C. hominis endocarditis were reported [32 37 ]. The main characteristics of C. hominis endocarditis are as follows: i) patients mean age was 50.2 + 15 years (range, 17-82), with a male-to-female sex ratio of ~2; ii) most common risk factors were underlying valve disease (61%, mostly congenital heart disease and rheumatic fever), and prosthetic valve (28%); iii) C. hominis endocarditis may be even more insidious than other HACEK endocarditis, with a mean diagnosis delay of 138 + 128 days according to Malani et al. [32] , and 169 days according to Wormser et al. [33] ; iv) the aortic valve is most commonly affected (52%), followed by the mitral valve (44%); v) main complications were heart failure (40%), and central nervous system emboli (21%); vi) valve replacement was required in 27 cases (45%), and the outcome was favourable in most cases (93% overall; 94% for the subgroup of patients with prosthetic valve endocarditis) [32] . Limited data on C. valvarum endocarditis would suggest that large vegetations and extensive valvular destruction are common [38] .
Eikenella corrodens
The genus Eikenella, within the family Neisseriaceae, includes the unique species E. corrodens. It is a facultatively anaerobic, non-motile, straight gram-negative small rod with rounded ends. It is a normal inhabitant of oral cavities of humans and some mammals from which it can be transmitted via saliva (bites, syringes). The prevalence carriage is higher among people under 20 years of age, and in those with periodontal disease.
Its association with endocarditis is rather weak, as i) this bacteria was responsible for only ~5% of all HACEK endocarditis reported from the Mayo clinic [2] , and in the ICE-prospective cohort study [7] ; ii) the PPV of E. corrodens bacteremia for the diagnosis of endocarditis is the lowest among all HACEK bacteria (none of 11 consecutive cases of E. corrodens bacteremia was related to endocarditis in one study) [4] ; iii) E. corrodens is involved in a broad spectrum of infectious diseases, including localized infections of the head and neck, upper or lower tract respiratory infections, subcutaneous abscesses, cellulitis, and osteomyelitis [39] . Interestingly, these latter have been especially reported following clenched fist injuries or human bites, due to the traumatic inoculation of E. corrodens originating from the oral microbiota [40] . In addition, IVDU is a risk factor for skin and skin structure or endovascular E. corrodens infections, due to the use of saliva for skin cleansing or dissolution of narcotics in some settings [41] . Endocarditis represented only 2% of all invasive infections due to E. corrodens in one study [39] .
A study of 17 clinical isolates of E. corrodens found susceptibility rates of 94% for penicillin and ampicillin, and 100% for ampicillin-sulbactam, amoxicillin-clavulanic acid, ceftriaxone, meropenem, and levofloxacin [19] .
Kingella spp.
Kingella spp. are also members of the Neisseriaceae family and consist of facultatively anaerobic, non-motile, short gram-negative rods with tapered ends. Occasionnally, they may be resistant to decolorization and appear as gram-positive bacteria. They are part of the normal microbiota of upper respiratory and genitourinary tracts in humans. Within the genus, K. kingae is the main species responsible for invasive diseases, although cases of K. denitrificans endocarditis have been reported [7] . K. kingae colonizes the oropharynx -but not the nasopharynx -of approximately 10% of children aged from 6 months to 4 years [5] , and may be transmitted via respiratory droplets between family members and other close contacts
As for E. corrodens, its association with endocarditis is rather weak, as i) this bacteria was responsible for 7% of HACEK endocarditis diagnosed during years 1970-1993 at the Mayo clinic [2] , and 5% in the ICE-prospective cohort study (2000) (2001) (2002) (2003) (2004) (2005) (2006) [7] ; ii) the PPV of K. kingae bacteremia for the diagnosis of endocarditis was estimated at 42% (8/19) [4] . The situation is strikingly different for young children (i.e., under four years of age), who are much more prone to Kingella spp. invasive diseases [5] : K. kingae is the most common cause of septic arthritis in this population, which may be related to a potent repeats-in toxin system (RTX), that exhibits a wide range of cytotoxic activity and is particularly deleterious for macrophages, leucocytes, and synovial cells [42] . A study of 143 consecutive patients with K. kingae infections diagnosed in southern Israel during years 1988-2013 found that septic arthritis, osteomyelitis or tenosynovitis were most commonly involved (55%), followed by occult bacteremia (39%). Only two patients (1% of all invasive K. kingae infections) were diagnosed with endocarditis [42] .
However, given the very low incidence of infective endocarditis in children, a literature review found that K. kingae was the most common cause of HACEK endocarditis in this population, at the same level as H. parainfluenzae (36% of all HACEK endocarditis). Children with K. kingae endocarditis had underlying heart disease in 62% of cases (mostly congenital), and 12/13 initially survived (92%), although two had neurological sequels (hemiplegia), and one died during cardiac surgery three months later [43] . Outbreaks of invasive infections due to K. kingae have been reported in children communities, with severe manifestations -including endocarditis and meningitis -and high prevalence of colonization, suggesting that some isolates may present with enhanced colonization fitness, increased transmissibility, and high virulence [44] .
Expert commentary
Although HACEK endocarditis has been first reported more than 50 years ago, and remains a rare clinical entity, totalling around 1-3% of all infective endocarditis [7 21 45-47] , this state-of-the-art Hospital during which time a special endocarditis blood culture protocol with extended incubation (up to 6 weeks) was implemented following physician requests in 215 patients: The 24 HACEK bacteria identified during that time (out of ~14,000 routine blood cultures), were all recovered within the standard 5-day incubation protocol [11] . Similar findings have been found with different blood culture systems [10 11 48-50] . The advent of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) may allow dramatic improvement in the identification of HACEK bacteria once blood cultures return positive, in terms of accuracy, and delay [14 18 ].
-Thirdly, a systematic study on the association between HACEK bacteremia and the probability of endocarditis [4] , found striking heterogeneity within the HACEK group: Indeed, the positive predictive value of positive blood culture(s) for the diagnosis of endocarditis ranged from 0% with E. corrodens bacteremia, to 100% for A. actinomycetemcomitans.
-Fourthly, a large multi-national, prospective cohort of 5,591 patients with definite infective endocarditis, found that the 77 cases of HACEK endocarditis (1.4% of the whole cohort), were significantly younger (median age, 47 vs. 61 years, P<0.001), had more vascular/immunologic manifestations (32% vs. 20%, P<0.008), and stroke (25% vs. 17%, P=0.05), but lower risk of heart failure (15% vs. 30%, P=0.004), in-hospital mortality (4% vs. 18%, P<0.001), and one-year mortality (6% vs. 20%, P=0.01) [7] . Importantly, the favourable outcome of both medically and surgically treated HACEK endocarditis on prosthetic valve demonstrates that these organisms are not a stand-alone indication for surgical valvular replacement (i.e. usual criteria for surgical treatment should apply, mostly heart failure, embolism risk, and medical treatment failure [22 51] ).
-Fifthly, β-lactamase-producing strains of HACEK may be emerging [19 52] , and difficulty in performing antimicrobial susceptibility testing as a result of failure of growth in vitro have led endocarditis experts to recommend that, 'unless growth is adequate for in vitro screening, then HACEK microorganisms should be considered ampicillin resistant, and penicillin and ampicillin should not be used to treat patients with IE in these cases' [22] . However, when reliable drugsusceptibility testing demonstrate that amoxicillin or ampicillin are effective in vitro, in the absence of β-lactamase production, one of these agent may be used instead of third generation cephalosporin [51] , as their narrower spectrum would imply a lower risk of drug-resistant bacteria selection, and a more limited impact on microbiota -hence a lower risk of Clostridium difficile colitis. The use of aminoglycoside is not recommended for HACEK endocarditis. Ciprofloxacin is the main alternative in patients who cannot tolerate β-lactam agents. The recommended duration of treatment is 4 weeks for native valve endocarditis, and six weeks for prosthetic valve endocarditis.
Five-year view
The field of HACEK endocarditis will probably experience limited development over the next 5 years. There is no reason why it would evolve as an emerging disease, given the very low and steady proportion of infective endocarditis that were related to these pathogens since the first descriptions of HACEK endocarditis more than 50 years ago. In addition, the changing profile of infective endocarditis since the early 2000's mostly favours the emergence of staphylococci endocarditis, as a consequence of medical progress. Current systems for blood cultures have resolved the need for extended incubation of blood culture bottles for the diagnosis of HACEK endocarditis, and the advent of new tools for rapid identification of bacteria (e.g. MALDI-TOF) have brought additional progress in the field, so that no dramatic improvement is expected to have any significant impact on the diagnosis of HACEK endocarditis over the next five years. Finally, current recommendations for treatment will probably not dramatically change as well, given the 100% susceptibility rate of HACEK bacteria to the first-line regimen currently recommended (third generation cephalosporin), and the favourable outcome in most cases, with the use of current criteria for surgical valvular replacement. 
Key issues

